Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


As Financial Turmoil Engulfs West, Germany’s Bayer Looks East To Form R&D Center In China

This article was originally published in The Pink Sheet Daily

Executive Summary

The center in Beijing will become the third in a triumvirate of global research sites that Bayer oversees, and its Chinese scientists will be closely linked with their colleagues in Germany and the U.S.

You may also be interested in...

U.S. Economic Crisis, Beijing’s Perks, Could Trigger Reverse Brain Drain

BEIJING - The financial meltdown and widening layoffs in the United States, combined with Beijing's injection of stimulus funds into its pharmaceutical and biotech sectors, could trigger a reverse brain drain in those sectors, according to industry insiders and investors in the U.S. and China

Bayer Gains China’s Go-Ahead To Sell Liver Cancer Drug Nexavar In World’s Biggest Potential Market

BEIJING - After receiving regulatory approval to sell the liver cancer drug Nexavar in China, executives at Bayer HealthCare Pharmaceuticals indicated the country could become the biggest market in the world for the compound

Bayer Schering Partners With Polish Biotech Firm To Provide Recombinant Insulin To China's Exploding Diabetics Population

Bayer's antidiabetes drug Glucobay (acarbose), an alpha-glucosidase inhibitor, is already one of the company's strongest products in China.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts